RecruitingPhase 2/3

Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization

Egypt165 participantsStarted 2025-10-10

Plain-language summary

The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder. The main question it aims to answer is: Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.

Who can participate

Age range18 Years – 35 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Advanced maternal age (\>40 years) or any other risk factor for Poor Ovarian Response (POR).
✓. ≤3 oocytes with a conventional stimulation protocol).
✓. An abnormal ovarian reserve test \[i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml\].

Exclusion criteria

✕. Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction.
✕. Any pelvic pathology such as hydrosalpinx, uterine anomaly.
✕. Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia

What they're measuring

The number of mature oocyte

Timeframe: 12 weeks

Trial details

NCT IDNCT07323329

SponsorBeni-Suef University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-15

View on ClinicalTrials.gov More Infertility trials